Summit Global Investments Eagle Pharmaceuticals, Inc. Transaction History

Summit Global Investments

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $15,508 - $27,659	587 Added 1.74%	34,325 $907,000
Q2 2022 Aug 23, 2022	BUY	$41.26 - $51.35 $64,159 - $79,849	1,555 Added 4.83%	33,738 $1.5 Million
Q1 2022 Apr 29, 2022	SELL	$44.58 - $52.6 $157,634 - $185,993	-3,536 Reduced 9.9%	32,183 $1.59 Million
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $68,730 - $85,350	-1,500 Reduced 4.03%	35,719 $1.82 Million
Q3 2021 Nov 08, 2021	SELL	$43.79 - $55.78 $48,169 - $61,358	-1,100 Reduced 2.87%	37,219 $2.08 Million
Q2 2021 Jan 28, 2022	SELL	$36.86 - $44.5 $5,381 - $6,497	-146 Reduced 0.38%	38,319 $1.64 Million
Q1 2021 Jan 27, 2022	BUY	$40.32 - $50.97 $283,086 - $357,860	7,021 Added 22.33%	38,465 $1.61 Million
Q4 2020 Feb 11, 2021	BUY	$41.72 - $51.34 $52,358 - $64,431	1,255 Added 4.16%	31,444 $1.46 Million
Q3 2020 Nov 16, 2020	BUY	$37.02 - $51.28 $81,036 - $112,251	2,189 Added 7.82%	30,189 $1.28 Million
Q2 2020 Aug 11, 2020	BUY	$43.24 - $55.02 $596,712 - $759,276	13,800 Added 97.18%	28,000 $1.34 Million
Q1 2020 May 14, 2020	BUY	$34.37 - $60.07 $488,053 - $852,994	14,200 New	14,200 $653,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

Stay updated on Summit Global Investments with notifications on news.